Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment

•We report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis, Parkinson's disease and cognitive impairment.•All patients were receiving treatments with either amantadine or memantine on stable registered doses.•In all patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders Jg. 42; S. 102163
Hauptverfasser: Rejdak, Konrad, Grieb, Paweł
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 01.07.2020
Schlagworte:
Adamantane - therapeutic use
Adamantanes
Adult
Aged
Aged, 80 and over
Amantadine
Amantadine - therapeutic use
Asymptomatic Infections
Betacoronavirus
Case Report
Cognitive Dysfunction - complications
Cognitive Dysfunction - drug therapy
Cognitive impairment
Coronavirus Infections - complications
Coronavirus Infections - physiopathology
COVID-19
Dopamine Agents - therapeutic use
Female
Humans
Male
Memantine
Memantine - therapeutic use
Middle Aged
Multiple sclerosis
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Neurology
Pandemics
Parkinson Disease - complications
Parkinson Disease - drug therapy
Pneumonia, Viral - complications
Pneumonia, Viral - physiopathology
Protection
Protective Factors
SARS-CoV-2
Severity of Illness Index
COVID-19
Adamantanes
Amantadine
Multiple sclerosis
SARS-CoV-2
Memantine
PD
Protection
Cognitive impairment
ISSN:2211-0348, 2211-0356, 2211-0356
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•We report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis, Parkinson's disease and cognitive impairment.•All patients were receiving treatments with either amantadine or memantine on stable registered doses.•In all patients infection with SARS-CoV-2 was confirmed by rtPCR but none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2211-0348
2211-0356
2211-0356
DOI:10.1016/j.msard.2020.102163